Stop Wasting our Money: Taking a Stand on the Lucentis vs Avastin Contraversy
In a previous blog post, I lamented about the high costs of using Lucentis in the treatment of macular degeneration over the much less expensive, but equally effacacious Avastin. I continually receive letters from retinal surgeons who are treating my patients with Lucentis as a primary modality.
Re: Lucentis Treatment of my patients
In receiving referral letters about my patients, most recently XXXX XXXXX, I notice that your group treats my SMD patients with Lucentis as a primary modality. I am concerned as to why you do not try Avastin first, based on the cost efficacy. I feel so strongly about this that I now inform all my patients of the economic impact on our healthcare system. I will also NOT refer patients to practices that use Lucentis as their drug of choice. I certainly do understand using Lucentis when Avastin is not working..
I am enclosing a copy of a post from my blog that fully explains my position on this matter. I would appreciate a call from someone in your practice to discuss this further so that I may again feel comfortable referring patients to your practice.
Cary M. Silverman, MD